Previous 10 | Next 10 |
2024-04-07 08:00:00 ET More on Phathom Pharmaceuticals Phathom: Undervalued Biotech With Possible GERD Treatment Label Expansion Phathom Pharmaceuticals, Inc. (PHAT) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Phathom Pharmaceuticals ...
2024-04-05 07:00:00 ET Biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) has been on fire over the past three years. The company has delivered solid clinical progress and an important regulatory approval, and its financial results have generally been robust excluding its corona...
2024-04-02 11:36:00 ET More on CRISPR Therapeutics Crispr Therapeutics: I'm Not Betting Against Gene Editing This Time (Upgrade) Crispr Therapeutics: Cautiously Optimistic CRISPR Therapeutics AG (CRSP) Presents at Citi 2024 Virtual Oncology Leadership Summit Conferen...
TARRYTOWN, N.Y., April 01, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its first quarter 2024 financial and operating results on Thursday, May 2, 2024, before the U.S. financial markets open. The Company will host a conference c...
2024-03-31 21:35:02 ET More on Regeneron, Sanofi Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate Sanofi: My Top Pick In Big Pharma Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners Global Biopharma Conference (Transcript) U.S. CDC warns...
2024-03-31 09:25:35 ET Summary The positive CHMP opinion could mean possible European Approval; European Commission expected to decide upon approval for this in the next few months. Phase 3 NORSE EIGHT study underway using ONS-5010 for the treatment of patients with Wet-AMD; Data ...
2024-03-28 13:11:15 ET More on Xeris Pharmaceuticals Xeris Biopharma (XERS) Q4 2023 Earnings Call Transcript Xeris Biopharma: Speculative Buy, Size Your Position Accordingly Xeris Biopharma Holdings Stock Is A Hold With Robust Performance Into 2024 Xeris Phar...
2024-03-28 08:00:00 ET Are stock splits back in style? About two years ago, a number of high-profile corporations made such moves after their shares rose to unwieldy levels. Now, Chipotle , one of the leading fast-casual restaurant chains, is on the verge of conducting a 50-for-1 stock ...
2024-03-26 14:36:26 ET Summary Regeneron Pharmaceuticals, Inc.'s Eylea HD reinforces its market dominance in treating wet AMD, competing effectively against biosimilars and Roche's Vabysmo. Libtayo's revenue growth is impressive, with expectations to become a blockbuster, enhancin...
2024-03-26 13:15:05 ET RBC Capital analyst issues BUY recommendation for REGN on March 26, 2024 10:01AM ET. The previous analyst recommendation was Buy. REGN was trading at $958.6051 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current...
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
2024-07-12 11:00:05 ET Trung Huynh from UBS issued a price target of $1,250.00 for REGN on 2024-07-12 10:18:00. The adjusted price target was set to $1,250.00. At the time of the announcement, REGN was trading at $1092.3075. The overall price target consensus is at $902....
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...